SINGLE PAYMENT OBLIGATION Sample Clauses

SINGLE PAYMENT OBLIGATION. Each of the foregoing milestones shall only be paid once regardless of the number of acceptances or Launches with respect to such Product, including multiple product forms of the same Compound, additional active or inactive ingredients, indications, modalities and/or dosage strengths.
Sample 1Sample 2Sample 3See All (4)
AutoNDA by SimpleDocs
SINGLE PAYMENT OBLIGATION. (a) Notwithstanding anything to the contrary herein, it is understood by the parties that if Xxxxxx ceases to develop a Development Compound prior to the payment of all of the milestones specified in Section 6.2 or if a Product is removed from the market prior to [**] (any such Development Compound or Product being referred to herein as a “Canceled Product”), and Xxxxxx decides to develop a different Development Compound that also modulates the [**] Target, then Xxxxxx shall, with respect to such other Development Compound, be obligated to pay only that/those milestone payment(s) which were not made with respect to the Canceled Product; provided however, if Xxxxxx does at some time in the future develop such Canceled Product, then appropriate adjustment with respect to milestone payments shall be made hereunder. (b) The milestone payments set forth in Section 6.2 shall not be made more than once with respect to any given Development Compound, regardless of the number of such filings, trials or approvals that may he undertaken or granted with respect to such Development Compound, including, without limitation, such activities with multiple product forms or formulations of the same Development Compound, combinations with different and/or additional active or inactive ingredients, additional indications, different delivery modalities and/or various dosage strengths.
Sample 1Sample 2Sample 3
SINGLE PAYMENT OBLIGATION. Each of the foregoing milestones set forth in Article 5.1 shall only be paid once regardless of the number of acceptances or Launches with respect to such Product, including multiple product forms of the same Compound, additional active or inactive ingredients, indications, modalities and/or dosage strengths. With respect to the foregoing milestones set forth in Article 5.1 (e) through (h), in the event that SuperGen achieves more than any of one such milestones within the same calendar year, SuperGen shall not be obligated to pay more than the first of such milestones in such calendar year. Subject to the foregoing, SuperGen shall pay subsequent milestones upon their achievement in subsequent years.
Sample 1Sample 2
SINGLE PAYMENT OBLIGATION. Each of the foregoing milestones shall only be paid once regardless of the number of *** with respect to such *** including multiple *** of the same *** additional ***.
Sample 1
SINGLE PAYMENT OBLIGATION. Each of the above milestone payments shall be payable once with respect to Products relating to a given Designated Gene/Gene Derivative, upon the first occurrence of the indicated milestone for such Product, and no additional payments shall be due upon subsequent or repeated achievement of the same milestone for a different Product in the same Field of Use under the same Designated Gene/Gene Derivative license. For example, if GHI develops two Diagnostic Products relating to the same Designated Gene and both such Diagnostic Products achieve a given milestone, the applicable payment will only be made once upon the first such occurrence.
Sample 1
SINGLE PAYMENT OBLIGATION. Each milestone payment set forth in Section 3.1 shall not be made more than once with respect to the Finished Product(s), regardless of the formulation(s) developed (e.g., the NaPro Formulated Product, Abbott Formulated Product or NaPro Oral Formulated Product) the numbex xx Xpplications for Regulatory Approval in the Territory, clinical trials or Regulatory Approvals that may be undertaken or granted with respect to the Finished Product(s), including, without limitation, such activities with multiple product forms or formulations of any Finished Product(s), combinations with different and/or additional active or inactive ingredients, additional indications, different delivery modalities and/or various dosage strengths. For the avoidance of doubt, in the event that the Abbott Formulated Product or NaPro Oral Formulated Product is pursued xxxxxr in lieu of or in addition to the NaPro Formulated Product, any milestone set forth in Section 3.1 shall be paid only once during the Term and shall not be paid again.
Sample 1
SINGLE PAYMENT OBLIGATION. It is understood that each of the milestone payments above in subparagraph (a) will not be made more than once, on the first instance only of attaining such milestone. For clarification, if multiple milestones are attained simultaneously or in the same calendar year, each milestone shall be due and payable at the time of its attainment.
Sample 1
AutoNDA by SimpleDocs
SINGLE PAYMENT OBLIGATION. It is understood that each of the milestone payments above in Section 3.3.1 will not be made more than once, on the first instance only of either Product (NAITgam or the T1 Antibody) attaining such milestone.
Sample 1
SINGLE PAYMENT OBLIGATION. Each of the above milestone payments shall be payable once with respect to Products relating to a given Designated Gene Product, upon the first occurrence of the indicated milestone for such Product, and no additional payments shall be due upon subsequent or repeated achievement of the same milestone for a different Product in the same Field of Use under the same Designated Gene Product license. For example, if diaDexus or its sublicensee develops two Drug Products relating to the same Designated Gene Product and both such Drug Products achieve a given ***** Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
Sample 1

Related to SINGLE PAYMENT OBLIGATION

  • Repayment Obligation In the event that any State and/or federal funds are deferred and/or disallowed as a result of any audits or expended in violation of the laws applicable to the expenditure of such funds, the Contractor shall be liable to the Agency for the full amount of any claim disallowed and for all related penalties incurred. The requirements of this paragraph shall apply to the Contractor as well as any subcontractors.

  • Payment Obligations Absolute The Company’s obligation during and after the Employment Period to pay the Executive the amounts and to make the benefit and other arrangements provided herein shall be absolute and unconditional and shall not be affected by any circumstances, including, without limitation, any setoff, counterclaim, recoupment, defense or other right which the Company may have against him or anyone else. Except as provided in Section 15, all amounts payable by the Company hereunder shall be paid without notice or demand. Each and every payment made hereunder by the Company shall be final, and the Company will not seek to recover all or any part of such payment from the Executive, or from whomsoever may be entitled thereto, for any reason whatsoever.

  • Payment of Reimbursement Obligations (a) The Borrower agrees to pay to the Administrative Agent for the account of the Issuing Bank the amount of all Advances for Reimbursement Obligations, interest and other amounts payable to the Issuing Bank under or in connection with any Facility Letter of Credit when due, irrespective of any claim, set-off, defense or other right which the Borrower may have at any time against any Issuing Bank or any other Person, under all circumstances, including without limitation any of the following circumstances: (i) any lack of validity or enforceability of this Agreement or any of the other Loan Documents; (ii) the existence of any claim, setoff, defense or other right which the Borrower may have at any time against a beneficiary named in a Facility Letter of Credit or any transferee of any Facility Letter of Credit (or any Person for whom any such transferee may be acting), the Administrative Agent, the Issuing Bank, any Lender, or any other Person, whether in connection with this Agreement, any Facility Letter of Credit, the transactions contemplated herein or any unrelated transactions (including any underlying transactions between the Borrower and the beneficiary named in any Facility Letter of Credit); (iii) any draft, certificate or any other document presented under the Facility Letter of Credit proving to be forged, fraudulent, invalid or insufficient in any respect of any statement therein being untrue or inaccurate in any respect; (iv) the surrender or impairment of any security for the performance or observance of any of the terms of any of the Loan Documents; or (v) the occurrence of any Default or Event of Default. (b) In the event any payment by the Borrower received by the Issuing Bank or the Administrative Agent with respect to a Facility Letter of Credit and distributed by the Administrative Agent to the Lenders on account of their participations is thereafter set aside, avoided or recovered from the Administrative Agent or Issuing Bank in connection with any receivership, liquidation, reorganization or bankruptcy proceeding, each Lender which received such distribution shall, upon demand by the Administrative Agent, contribute such Lender's Percentage of the amount set aside, avoided or recovered together with interest at the rate required to be paid by the Issuing Bank or the Administrative Agent upon the amount required to be repaid by the Issuing Bank or the Administrative Agent.

  • Unpaid Reimbursement Obligation Any Reimbursement Obligation for which the applicable Borrower does not reimburse the Administrative Agent and the Lenders on the date specified in, and in accordance with, §4.

  • Payment Obligation The RTOs each assume responsibility for ensuring that their respective payment obligations resulting from the M2M coordination process set forth in Schedule D to this Agreement are satisfied without regard for their ability to collect such payments from their respective customers.

  • Depositor Payment Obligation The Depositor shall be responsible for payment of the Administrator’s compensation under the Administration Agreement and shall reimburse the Administrator for all expenses and liabilities of the Administrator incurred under the Administration Agreement.

  • The Companys Payment Obligation The Company’s obligation to make the payments and the arrangements provided for herein will be absolute and unconditional, and will not be affected by any circumstances, including, without limitation, any offset, counterclaim, recoupment, defense, or other right which the Company may have against the Executive or anyone else. All amounts payable by the Company hereunder will be paid without notice or demand. Each and every payment made hereunder by the Company will be final, and the Company will not seek to recover all or any part of such payment from the Executive or from whomsoever may be entitled thereto, for any reasons whatsoever. The Executive will not be obligated to seek other employment in mitigation of the amounts payable or arrangements made under any provision of this Agreement, and the obtaining of any such other employment will in no event effect any reduction of the Company’s obligations to make the payments and arrangements required to be made under this Agreement, except to the extent provided in Sections 3.3(e) and (f) herein. Notwithstanding anything in this Agreement to the contrary, if Severance Benefits are paid under this Agreement, no severance benefits under any program of the Company, other than benefits described in this Agreement, will be paid to the Executive.

  • Sharing of Reimbursement Obligation Payments Whenever the Agent receives a payment from the Borrower on account of reimbursement obligations in respect of a Letter of Credit or Credit Support as to which the Agent has previously received for the account of the Letter of Credit Issuer thereof payment from a Lender, the Agent shall promptly pay to such Lender such Lender’s Pro Rata Share of such payment from the Borrower. Each such payment shall be made by the Agent on the next Settlement Date.

  • Joint Obligation If there be more than one Tenant the obligations hereunder imposed upon Tenants shall be joint and several.

  • Reimbursement Obligation The Borrower agrees unconditionally, irrevocably and absolutely to pay immediately to the Agent, for the account of the Lenders, the amount of each advance which may be drawn under or pursuant to a Letter of Credit or an L/C Draft related thereto (such obligation of the Borrower to reimburse the Agent for an advance made under a Letter of Credit or L/C Draft being hereinafter referred to as a "REIMBURSEMENT OBLIGATION" with respect to such Letter of Credit or L/C Draft). If the Borrower at any time fails to repay a Reimbursement Obligation pursuant to this SECTION 3.6, the Borrower shall be deemed to have elected to borrow Revolving Loans from the Lenders, as of the date of the advance giving rise to the Reimbursement Obligation, equal in amount to the amount of the unpaid Reimbursement Obligation. Such Revolving Loans shall be made as of the date of the payment giving rise to such Reimbursement Obligation, automatically, without notice and without any requirement to satisfy the conditions precedent otherwise applicable to an Advance of Revolving Loans. Such Revolving Loans shall constitute a Floating Rate Advance, the proceeds of which Advance shall be used to repay such Reimbursement Obligation. If, for any reason, the Borrower fails to repay a Reimbursement Obligation on the day such Reimbursement Obligation arises and, for any reason, the Lenders are unable to make or have no obligation to make Revolving Loans, then such Reimbursement Obligation shall bear interest from and after such day, until paid in full, at the interest rate applicable to a Floating Rate Advance.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!